Gene
Entrez ID Entrez Gene ID - the GENE ID in NCBI Gene database.
84059
Gene name Gene Name - the full gene name approved by the HGNC.
Adhesion G protein-coupled receptor V1
Gene symbol Gene Symbol - the official gene symbol approved by the HGNC.
ADGRV1
Synonyms (NCBI Gene) Gene synonyms aliases
FEB4, GPR98, MASS1, USH2B, USH2C, VLGR1, VLGR1b
Chromosome Chromosome number
5
Chromosome location Chromosomal Location - indicates the cytogenetic location of the gene or region on the chromosome.
5q14.3
Summary Summary of gene provided in NCBI Entrez Gene.
This gene encodes a member of the G-protein coupled receptor superfamily. The encoded protein contains a 7-transmembrane receptor domain, binds calcium and is expressed in the central nervous system. Mutations in this gene are associated with Usher syndro
SNPs SNP information provided by dbSNP.
SNP ID Visualize variation Clinical significance Consequence
rs41302834 G>A,T Conflicting-interpretations-of-pathogenicity, uncertain-significance, benign, benign-likely-benign Non coding transcript variant, genic upstream transcript variant, 5 prime UTR variant, coding sequence variant, missense variant
rs41303344 G>A Likely-pathogenic, benign-likely-benign Non coding transcript variant, coding sequence variant, genic upstream transcript variant, missense variant
rs41303352 A>C,G,T Likely-benign, benign, conflicting-interpretations-of-pathogenicity Non coding transcript variant, genic upstream transcript variant, 5 prime UTR variant, coding sequence variant, missense variant
rs41305898 C>T Likely-benign, conflicting-interpretations-of-pathogenicity Non coding transcript variant, coding sequence variant, genic upstream transcript variant, missense variant
rs41308297 A>G Likely-benign, conflicting-interpretations-of-pathogenicity Non coding transcript variant, coding sequence variant, missense variant
Gene ontology (GO) Gene ontology information of associated ontologies with gene provided by GO database.
GO ID Ontology Definition Evidence Reference
GO:0001917 Component Photoreceptor inner segment IEA
GO:0001965 Function G-protein alpha-subunit binding IBA
GO:0001965 Function G-protein alpha-subunit binding ISS
GO:0002141 Component Stereocilia ankle link ISS
GO:0002142 Component Stereocilia ankle link complex ISS
Other IDs Other ids provides unique ids of gene in databases such as OMIM, HGNC, ENSEMBLE.
MIM HGNC e!Ensembl
602851 17416 ENSG00000164199
Protein
UniProt ID Q8WXG9
Protein name Adhesion G-protein coupled receptor V1 (ADGRV1) (EC 3.4.-.-) (G-protein coupled receptor 98) (Monogenic audiogenic seizure susceptibility protein 1 homolog) (Usher syndrome type-2C protein) (Very large G-protein coupled receptor 1) [Cleaved into: ADGRV1 s
Protein function G-protein coupled receptor which has an essential role in the development of hearing and vision. Couples to G-alpha(i)-proteins, GNAI1/2/3, G-alpha(q)-proteins, GNAQ, as well as G-alpha(s)-proteins, GNAS, inhibiting adenylate cyclase (AC) activi
Family and domains

Pfam

Accession ID Position in sequence Description Type
PF03160 Calx-beta 30 117 Calx-beta domain Domain
PF03160 Calx-beta 133 237 Calx-beta domain Domain
PF03160 Calx-beta 252 363 Calx-beta domain Domain
PF03160 Calx-beta 379 488 Calx-beta domain Domain
PF03160 Calx-beta 666 746 Calx-beta domain Domain
PF03160 Calx-beta 763 861 Calx-beta domain Domain
PF03160 Calx-beta 876 979 Calx-beta domain Domain
PF03160 Calx-beta 993 1093 Calx-beta domain Domain
PF03160 Calx-beta 1107 1208 Calx-beta domain Domain
PF13385 Laminin_G_3 1336 1496 Domain
PF03160 Calx-beta 1496 1546 Calx-beta domain Domain
PF03160 Calx-beta 1561 1666 Calx-beta domain Domain
PF03160 Calx-beta 1724 1809 Calx-beta domain Domain
PF03160 Calx-beta 1851 1952 Calx-beta domain Domain
PF03160 Calx-beta 1965 2079 Calx-beta domain Domain
PF03160 Calx-beta 2106 2206 Calx-beta domain Domain
PF03160 Calx-beta 2221 2324 Calx-beta domain Domain
PF03160 Calx-beta 2481 2543 Calx-beta domain Domain
PF03160 Calx-beta 2594 2676 Calx-beta domain Domain
PF03160 Calx-beta 2691 2790 Calx-beta domain Domain
PF03160 Calx-beta 2814 2925 Calx-beta domain Domain
PF03160 Calx-beta 2947 3048 Calx-beta domain Domain
PF03160 Calx-beta 3064 3172 Calx-beta domain Domain
PF03736 EPTP 3395 3438 EPTP domain Repeat
PF03160 Calx-beta 3582 3626 Calx-beta domain Domain
PF03160 Calx-beta 3640 3740 Calx-beta domain Domain
PF03160 Calx-beta 3783 3875 Calx-beta domain Domain
PF03160 Calx-beta 3901 4006 Calx-beta domain Domain
PF03160 Calx-beta 4020 4123 Calx-beta domain Domain
PF03160 Calx-beta 4255 4354 Calx-beta domain Domain
PF03160 Calx-beta 4386 4489 Calx-beta domain Domain
PF03160 Calx-beta 4660 4735 Calx-beta domain Domain
PF03160 Calx-beta 4996 5095 Calx-beta domain Domain
PF03160 Calx-beta 5280 5333 Calx-beta domain Domain
PF03160 Calx-beta 5484 5599 Calx-beta domain Domain
PF00002 7tm_2 5908 6148 7 transmembrane receptor (Secretin family) Family
Tissue specificity TISSUE SPECIFICITY: Expressed at low levels in adult tissues. {ECO:0000269|PubMed:10976914}.
Sequence
MSVFLGPGMPSASLLVNLLSALLILFVFGETEIRFTGQTEFVVNETSTTVIRLIIERIGE
PANVTAIVSLYGEDAGDFFDTYAAAFIPAGETNRTVYIAVCDDDLPEPDETFIFHLT
LQK
PSANVKLGWPRTVTVTILSNDNAFGIISFNMLPSIAVSEPKGRNESMPLTLIREKGTYGM
VMVTFEVEGGPNPPDEDLSPVKGNITFPPGRATVIYNLTVLDDEVPENDEIFLIQLK
SVE
GGAEINTSRNSIEIIIKKNDSPVRFLQSIYLVPEEDHILIIPVVRGKDNNGNLIGSDEYE
VSISYAVTTGNSTAHAQQNLDFIDLQPNTTVVFPPFIHESHLKFQIVDDTIPEIAESFHI
MLL
KDTLQGDAVLISPSVVQVTIKPNDKPYGVLSFNSVLFERTVIIDEDRISRYEEITVV
RNGGTHGNVSANWVLTRNSTDPSPVTADIRPSSGVLHFAQGQMLATIPLTVVDDDLPEEA
EAYLLQIL
PHTIRGGAEVSEPAELLFYIQDSDDVYGLITFFPMENQKIESSPGERYLSLS
FTRLGGTKGDVRLLYSVLYIPAGAVDPLQAKEGILNISRRNDLIFPEQKTQVTTKLPIRN
DAFLQNGAHFLVQLETVELLNIIPLIPPISPRFGEICNISLLVTPAIANGEIGFLSNLPI
ILHEPEDFAAEVVYIPLHRDGTDGQATVYWSLKPSGFNSKAVTPDDIGPFNGSVLFLSGQ
SDTTINITIKGDDIPEMNETVTLSLD
RVNVENQVLKSGYTSRDLIILENDDPGGVFEFSP
ASRGPYVIKEGESVELHIIRSRGSLVKQFLHYRVEPRDSNEFYGNTGVLEFKPGEREIVI
TLLARLDGIPELDEHYWVVLS
SHGERESKLGSATIVNITILKNDDPHGIIEFVSDGLIVM
INESKGDAIYSAVYDVVRNRGNFGDVSVSWVVSPDFTQDVFPVQGTVVFGDQEFSKNITI
YSLPDEIPEEMEEFTVILL
NGTGGAKVGNRTTATLRIRRNDDPIYFAEPRVVRVQEGETA
NFTVLRNGSVDVTCMVQYATKDGKATARERDFIPVEKGETLIFEVGSRQQSISIFVNEDG
IPETDEPFYIILL
NSTGDTVVYQYGVATVIIEANDDPNGIFSLEPIDKAVEEGKTNAFWI
LRHRGYFGSVSVSWQLFQNDSALQPGQEFYETSGTVNFMDGEEAKPIILHAFPDKIPEFN
EFYFLKLV
NISGGSPGPGGQLAETNLQVTVMVPFNDDPFGVFILDPECLEREVAEDVLSE
DDMSYITNFTILRQQGVFGDVQLGWEILSSEFPAGLPPMIDFLLVGIFPTTVHLQQHMRR
HHSGTDALYFTGLEGAFGTVNPKYHPSRNNTIANFTFSAWVMPNANTNGFIIAKDDGNGS
IYYGVKIQTNESHVTLSLHYKTLGSNATYIAKTTVMKYLEESVWLHLLIILEDGIIEFYL
DGNAMPRGIKSLKGEAITDGPGILRIGAGINGNDRFTGLMQDVRSYERKLTLEEI
YELHA
MPAKSDLHPISGYLEFRQGETNKSFIISARDDNDEEGEELFILKLV
SVYGGARISEENTT
ARLTIQKSDNANGLFGFTGACIPEIAEEGSTISCVVERTRGALDYVHVFYTISQIETDGI
NYLVDDFANASGTITFLPWQRSEVLNIYVLDDDIPELNEYFRVTLV
SAIPGDGKLGSTPT
SGASIDPEKETTDITIKASDHPYGLLQFSTGLPPQPKDAMTLPASSVPHITVEEEDGEIR
LLVIRAQGLLGRVTAEFRTVSLTAFSPEDYQNVAGTLEFQPGERYKYIFINITDNSIPEL
EKSFKVELL
NLEGGVAELFRVDGSGSGDGDMEFFLPTIHKRASLGVASQILVTIAASDHA
HGVFEFSPESLFVSGTEPEDGYSTVTLNVIRHHGTLSPVTLHWNIDSDPDGDLAFTSGNI
TFEIGQTSANITVEILPDEDPELDKAFSVSVL
SVSSGSLGAHINATLTVLASDDPYGIFI
FSEKNRPVKVEEATQNITLSIIRLKGLMGKVLVSYATLDDMEKPPYFPPNLARATQGRDY
IPASGFALFGANQSEATIAISILDDDEPERSESVFIELL
NSTLVAKVQSRSIPNSPRLGP
KVETIAQLIIIANDDAFGTLQLSAPIVRVAENHVGPIINVTRTGGAFADVSVKFKAVPIT
AIAGEDYSIASSDVVLLEGETSKAVPIYVINDIYPELEESFLVQLM
NETTGGARLGALTE
AVIIIEASDDPYGLFGFQITKLIVEEPEFNSVKVNLPIIRNSGTLGNVTVQWVATINGQL
ATGDLRVVSGNVTFAPGETIQTLLLEVLADDVPEIEEVIQVQLT
DASGGGTIGLDRIANI
IIPANDDPYGTVAFAQMVYRVQEPLERSSCANITVRRSGGHFGRLLLFYSTSDIDVVALA
MEEGQDLLSYYESPIQGVPDPLWRTWMNVSAVGEPLYTCATLCLKEQACSAFSFFSASEG
PQCFWMTSWISPAVNNSDFWTYRKNMTRVASLFSGQAVAGSDYEPVTRQWAIMQEGDEFA
NLTVSILPDDFPEMDESFLISLL
EVHLMNISASLKNQPTIGQPNISTVVIALNGDAFGVF
VIYNISPNTSEDGLFVEVQEQPQTLVELMIHRTGGSLGQVAVEWRVVGGTATEGLDFIGA
GEILTFAEGETKKTVILTILDDSEPEDDESIIVSLV
YTEGGSRILPSSDTVRVNILANDN
VAGIVSFQTASRSVIGHEGEILQFHVIRTFPGRGNVTVNWKIIGQNLELNFANFSGQLFF
PEGSLNTTLFVHLLDDNIPEEKEVYQVILY
DVRTQGVPPAGIALLDAQGYAAVLTVEASD
EPHGVLNFALSSRFVLLQEANITIQLFINREFGSLGAINVTYTTVPGMLSLKNQTVGNLA
EPEVDFVPIIGFLILEEGETAAAINITILEDDVPELEEYFLVNLT
YVGLTMAASTSFPPR
LDSEGLTAQVIIDANDGARGVIEWQQSRFEVNETHGSLTLVAQRSREPLGHVSLFVYAQN
LEAQVGLDYIFTPMILHFADGERYKNVNIMILDDDIPEGDEKFQLILT
NPSPGLELGKNT
IALIIVLANDDGPGVLSFNNSEHFFLREPTALYVQESVAVLYIVREPAQGLFGTVTVQFI
VTEVNSSNESKDLTPSKGYIVLEEGVRFKALQISAILDTEPEMDEYFVCTLF
NPTGGARL
GVHVQTLITVLQNQAPLGLFSISAVENRATSIDIEEANRTVYLNVSRTNGIDLAVSVQWE
TVSETAFGMRGMDVVFSVFQSFLDESASGWCFFTLENLIYGIMLRKSSVTVYRWQGIFIP
VEDLNIENPKTCEAFNIGFSPYFVITHEERNEEKPSLNSVFTFTSGFKLFLVQTIIILES
SQVRYFTSDSQDYLIIASQRDDSELTQVFRWNGGSFVLHQKLPVRGVLTVALFNKGGSVF
LAISQANARLNSLLFRWS
GSGFINFQEVPVSGTTEVEALSSANDIYLIFAENVFLGDQNS
IDIFIWEMGQSSFRYFQSVDFAAVNRIHSFTPASGIAHILLIGQDMSALYCWNSERNQFS
FVLEVPSAYDVASVTVKSLNSSKNLIALVGAHSHIYELAYISSHSDFIPSSGELIFEPGE
REATIAVNILDDTVPEKEESFKVQLK
NPKGGAEIGINDSVTITILSNDDAYGIVAFAQNS
LYKQVEEMEQDSLVTLNVERLKGTYGRITIAWEADGSISDIFPTSGVILFTEGQVLSTIT
LTILADNIPELSEVVIVTLT
RITTEGVEDSYKGATIDQDRSKSVITTLPNDSPFGLVGWR
AASVFIRVAEPKENTTTLQLQIARDKGLLGDIAIHLRAQPNFLLHVDNQATENEDYVLQE
TIIIMKENIKEAHAEVSILPDDLPELEEGFIVTIT
EVNLVNSDFSTGQPSVRRPGMEIAE
IMIEENDDPRGIFMFHVTRGAGEVITAYEVPPPLNVLQVPVVRLAGSFGAVNVYWKASPD
SAGLEDFKPSHGILEFADKQVTAMIEITIIDDAEFELTETFNISLI
SVAGGGRLGDDVVV
TVVIPQNDSPFGVFGFEEKTVMIDESLSSDDPDSYVTLTVVRSPGGKGTVRLEWTIDEKA
KHNLSPLNGTLHFDETESQKTIVLHTLQDTVLEEDRRFTIQLI
SIDEVEISPVKGSASII
IRGDKRASGEVGIAPSSRHILIGEPSAKYNGTAIISLVRGPGILGEVTVFWRIFPPSVGE
FAETSGKLTMRDEQSAVIVVIQALNDDIPEEKSFYEFQLTAVSEGGVLSESSSTANITVV
ASDSPYGRFAFSHEQLRVSEAQRVNITIIRSSGDFGHVRLWYKTMSGTAEAGLDFVPAAG
ELLFEAGEMRKSLHVEILDDDYPEGPEEFSLTIT
KVELQGRGYDFTIQENGLQIDQPPEI
GNISIVRIIIMKNDNAEGIIEFDPKYTAFEVEEDVGLIMIPVVRLHGTYGYVTADFISQS
SSASPGGVDYILHGSTVTFQHGQNLSFINISIIDDNESEFEEPIEILLT
GATGGAVLGRH
LVSRIIIAKSDSPFGVIRFLNQSKISIANPNSTMILSLVLERTGGLLGEIQVNWETVGPN
SQEALLPQNRDIADPVSGLFYFGEGEGGVRTIILTIYPHEEIEVEETFIIKLHLVKGEAK
LDSRAKDVTLTIQEFGDPNGVVQFAPETLSKKTYSEPLALEGPLLITFFVRRVKGTFGEI
MVYWELSSEFDITEDFLSTSGFFTIADGESEASFDVHLLPDEVPEIEEDYVIQLV
SVEGG
AELDLEKSITWFSVYANDDPHGVFALYSDRQSILIGQNLIRSIQINITRLAGTFGDVAVG
LRISSDHKEQPIVTENAERQLVVKDGATYKVDVVPIKNQVFLSLGSNFTLQLVTVMLVGG
RFYGMPTILQEAKSAVLPVSEKAANSQVGFESTAFQLMNITAGTSHVMISRRGTYGALSV
AWTTGYAPGLEIPEFIVVGNMTPTLGSLSFSHGEQRKGVFLWTFPSPGWPEAFVLHLSGV
QSSAPGGAQLRSGFIVAEIEPMGVFQFSTSSRNIIVSEDTQMIRLHVQRLFGFHSDLIKV
SYQTTAGSAKPLEDFEPVQNGELFFQKFQTEVDFEITIINDQLSEIEEFFYINLT
SVEIR
GLQKFDVNWSPRLNLDFSVAVITILDNDDLAGMDISFPETTVAVAVDTTLIPVETESTTY
LSTSKTTTILQPTNVVAIVTEATGVSAIPEKLVTLHGTPAVSEKPDVATVTANVSIHGTF
SLGPSIVYIEEEMKNGTFNTAEVLIRRTGGFTGNVSITVKTFGERCAQMEPNALPFRGIY
GISNLTWAVEEEDFEEQTLTLIFLDGERERKVSVQILDDDEPEGQEFFYVFLT
NPQGGAQ
IVEEKDDTGFAAFAMVIITGSDLHNGIIGFSEESQSGLELREGAVMRRLHLIVTRQPNRA
FEDVKVFWRVTLNKTVVVLQKDGVNLVEELQSVSGTTTCTMGQTKCFISIELKPEKVPQV
EVYFFVELYEATAGAAINNSARFAQIKILESDESQSLVYFSVGSRLAVAHKKATLISLQV
ARDSGTGLMMSVNFSTQELRSAETIGRTIISPAISGKDFVITEGTLVFEPGQRSTVLDVI
LTPETGSLNSFPKRFQIVL
FDPKGGARIDKVYGTANITLVSDADSQAIWGLADQLHQPVN
DDILNRVLHTISMKVATENTDEQLSAMMHLIEKITTEGKIQAFSVASRTLFYEILCSLIN
PKRKDTRGFSHFAEVTENFAFSLLTNVTCGSPGEKSKTILDSCPYLSILALHWYPQQING
HKFEGKEGDYIRIPERLLDVQDAEIMAGKSTCKLVQFTEYSSQQWFISGNNLPTLKNKVL
SLSVKGQSSQLLTNDNEVLYRIYAAEPRIIPQTSLCLLWNQAAASWLSDSQFCKVVEETA
DYVECACSHMSVYAVYARTDNLSSYNEAFFTSGFICISGLCLAVLSHIFCARYSMFAAKL
LTHMMAASLGTQILFLASAYASPQLAEESCSAMAAVTHYLYLCQFSWMLIQSVNFWYVLV
MNDEHTERRYLLFFLLSWGLPAFVVILLIVILKGIYHQSMSQIYGLIHGDLCFIPNVYAA
LFTAALVPLTCLVVVFVVFIHAYQVKPQWKAYDDVFRGRTNAAEIPLILYLFALISVTWL
WGGLHMAYRHFWMLVLFVIFNSLQGLYV
FMVYFILHNQMCCPMKASYTVEMNGHPGPSTA
FFTPGSGMPPAGGEISKSTQNLIGAMEEVPPDWERASFQQGSQASPDLKPSPQNGATFPS
SGGYGQGSLIADEESQEFDDLIFALKTGAGLSVSDNESGQGSQEGGTLTDSQIVELRRIP
IADTHL
Sequence length 6306
Interactions View interactions
<
Associated diseases Disease associations categorized as Causal (pathogenic variants), Unknown (uncertain genetic evidence), or Text Mining (literature-based associations)
Causal Diseases caused by PATHOGENIC or LIKELY PATHOGENIC variants from ClinVar only
Disease merge term Disease name dbSNP ID References
Febrile seizures Febrile seizures, familial, 4 rs765574676, rs121909761 N/A
retinal dystrophy Retinal dystrophy rs769286352, rs796051866, rs1292664749, rs1754556067, rs777309662, rs1755688091, rs778188580, rs878853348, rs371981035, rs1758488956, rs752179149, rs769215629, rs1764301206, rs765376986, rs1307312865
View all (5 more)
N/A
Retinitis Pigmentosa retinitis pigmentosa rs1581312596, rs1432643009 N/A
Usher Syndrome Usher syndrome type 2C, usher syndrome, usher syndrome type 2, usher syndrome type 1 rs527236131, rs1554090072, rs1580864592, rs527236133, rs777309662, rs764583867, rs765574676, rs796051867, rs1580905929, rs869312178, rs1581041519, rs1561660434, rs1581711527, rs1057519383, rs1554117973
View all (37 more)
N/A
Unknown Includes: (1) ClinVar NON-pathogenic variants (Uncertain, Benign, Conflicting, VUS), (2) GenCC associations, (3) GWAS associations, (4) CBGDA evidence-based associations. NOTE: Diseases with pathogenic evidence are excluded to avoid conflicts.
Disease merge term Disease name Evidence References Source
Cervical Cancer Cervical cancer N/A N/A GWAS
Epilepsy idiopathic generalized epilepsy N/A N/A ClinVar
hearing impairment Hearing impairment N/A N/A ClinVar
Melanoma Melanoma N/A N/A GWAS
Associations from Text Mining Disease associations identified through Pubtator
Disease Name Relationship Type References
Adenocarcinoma of Lung Associate 36793937
Alzheimer Disease Associate 35630584
Breast Neoplasms Associate 40473728
Carcinogenesis Associate 40473728
Ciliary Motility Disorders Associate 28927820
Deaf Blind Disorders Associate 31046701, 35630584
Deafness Associate 23767834, 23967202, 25719458, 32048449, 34997062, 35062939
DiGeorge Syndrome Associate 29025761
Epilepsy Associate 19471318, 29261713, 35630584, 36399868
Epilepsy Rolandic Associate 36399868